Abstract: The present application describes a two-step drug delivery formulation comprising a high affinity interaction between a drug conjugate and a compound, followed by introduction of a second compound with higher affinity to the drug conjugate to facilitate drug release. Delivery methods and specific interactions are also described.

Abstract: The present application describes a two-step drug delivery formulation comprising a high affinity interaction between a drug conjugate and a compound, followed by introduction of a second compound with higher affinity to the drug conjugate to facilitate drug release. Delivery methods and specific interactions are also described.

Abstract: The present application describes a two-step drug delivery formulation comprising a high affinity interaction between a drug conjugate and a compound, followed by introduction of a second compound with higher affinity to the drug conjugate to facilitate drug release. Delivery methods and specific interactions are also described.

Abstract: The present application describes a two-step drug delivery formulation comprising a high affinity interaction between a drug conjugate and a compound, followed by introduction of a second compound with higher affinity to the drug conjugate to facilitate drug release. Delivery methods and specific interactions are also described.

Abstract: A composition that achieves sustained oral drug release is provided. The composition includes liposomes, micelles, or polymeric particles, for example, having a hydrophobic core and an amphipathic corona, wherein the core contains a therapeutic, diagnostic, nutraceutical, cosmeceutical or prophylactic agent to be released, and the corona has targeting ligands immobilized to it. In a preferred embodiment the targeting ligands are bisphosphonate molecules, which enable binding to hydroxyapatite present on teeth. The incorporation of short polyethylene glycol (PEG) chains prevents chain entanglement and ionic interactions, minimizes mucus adhesion, increases particle diffusion rates in mucus, and increases the overall stability of particles in saliva. In a preferred embodiment the agent incorporated is a dental bleaching agent and the ligands selectively bind hydroxyapatite.

Abstract: A chemically patterned modified hydrogel formed from a modified hydrogel is provided. The hydrogel is conjugated with a multiphoton photocleavable molecule. The molecule has a multiphoton-labile protective group and a protected group. The protective group is cleavable upon multiphoton excitation to deprotect the protected group, without substantial polymerization of the hydrogel. The chemically patterned modified hydrogel is formed by exposing the modified hydrogel to multiphoton excitation to deprotect a portion of the protected groups.

Abstract: A chemically patterned modified hydrogel formed from a modified hydrogel is provided. The hydrogel is conjugated with a multiphoton photocleavable molecule. The molecule has a multiphoton-labile protective group and a protected group. The protective group is cleavable upon multiphoton excitation to deprotect the protected group, without substantial polymerization of the hydrogel. The chemically patterned modified hydrogel is formed by exposing the modified hydrogel to multiphoton excitation to deprotect a portion of the protected groups.